Paola Agueda Camargo Mamani

Ms. Paola Agueda Camargo Mamani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DMDolores Ochoa Mazarro
Dolores Ochoa Mazarro
MRManuel Román
Manuel Román
SVSamuel Martín Vílchez
Samuel Martín Vílchez
SLSergio Luquero-Bueno
Sergio Luquero-Bueno
PMPaola Agueda Camargo Mamani
Paola Agueda Camargo Mamani
Inmaculada GilaberteInmaculada Gilaberte
Inmaculada Gilaberte
Background/Objectives: Ulcerative colitis (UC), a chronic inflammatory bowel disease, affects approximately 5 million individuals worldwide, exerting a considerable influence on global health and economic systems. Among the challenges in UC management, treatment non-adherence stands out as a critical issue, often compromising therapeutic efficacy. One strategy to address this challenge is by reducing pill burden, which may improve patient compliance and optimize treatment outcomes. Methods: This randomized, two-sequence, four-period, crossover replicate study evaluated the pharmacokinetic profiles, bioequivalence, and safety of a newly developed 1500 mg mesalazine gastro-resistant tablet compared to three of the reference 500 mg Claversal® gastro-resistant tablets (total dose 1500 mg) in 80 healthy participants under fasted conditions. Results: Bioequivalence between mesalazine formulations was observed in both the rate and extent of systemic bioavailability. The geometric mean ratios and their 90% CI were 102.51% (95.85–109.63) for AUC0–∞, 103.36% (96.40–110.83) for AUC0–t, 84.49% (78.24–91.24) for AUC8–48h, and 114.24% (100.15–130.32) for Cmax. All within the accepted bioequivalence ranges, confirming comparable pharmacokinetic performance. Secondary pharmacokinetic parameters such as tmax, t1/2, Ke, Cl, and MRT were also consistent across both formulations. The incidence of adverse events was comparable between the two mesalazine formulations, with only flatulence and mild self-limited rash considered possibly related to test treatment. Conclusions: Overall, the 1500 mg formulation demonstrated a pharmacokinetic profile and tolerability comparable to the reference formulation, offering a higher-strength option to reduce daily pill burden. This strategy is of clinical relevance, particularly for improving treatment adherence among UC patients who need to take multiple pills daily to achieve their required dosage. While adherence is influenced by various factors, reducing pill burden may facilitate compliance and optimize therapeutic efficacy.

1 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
ARAna Ascaso del Río
Ana Ascaso del Río
PMPaola Agueda Camargo Mamani
Paola Agueda Camargo Mamani
Inmaculada GilaberteInmaculada Gilaberte
Inmaculada Gilaberte
MDMónica Díez-Hochleitner
Mónica Díez-Hochleitner
LVLeonor Laredo Velasco
Leonor Laredo Velasco
APAntonio Portoles
Antonio Portoles
Objective: This study aimed to assess the bioequivalence of two oral methocarbamol formulations, as follows: the test (T) methocarbamol 1500 mg tablets and the reference (R) Robaxin® 500 mg tablets (3 tablets, total dose: 1500 mg) under fasting conditions, and compare their pharmacokinetic performance. Methods: This was a single-center, phase I, randomized, open-label (blinded for analytical determination), two-sequence, two-period, crossover, bioequivalence study. A total of 32 healthy volunteers were randomly assigned to receive the T-R or R-T administration sequence. Each volunteer received a single dose of each methocarbamol formulation (T or R) separated by a washout period of 7 days. To evaluate the pharmacokinetic profile, blood samples were collected at nineteen time points after dosing. Results: The arithmetic mean Cmax was 31.72 µg/mL for R and 32.39 µg/mL for T, and the arithmetic mean AUC0−t was 90.25 h × µg/mL and 89.72 h × µg/mL, respectively. All adverse events reported were mild for both formulations. The 90% confidence intervals for the corresponding logarithmically transformed geometric mean ratios of Cmax and AUC0−t fell within the acceptance interval of 80.00–125.00%, as their values were 91.67–112.47% for ln(Cmax) and 92.34–103.47% for ln(AUC0−t). Conclusion: Therefore, one tablet of methocarbamol 1500 mg was found to be bioequivalent to the Robaxin® 500 mg tablets (3 tablets), with comparable tolerability and safety profiles.